350 filings
Page 3 of 18
8-K
6huaqb65cb9e24 7ccnb
10 Dec 20
Submission of Matters to a Vote of Security Holders
4:30pm
424B5
itc4inwvvs3
3 Dec 20
Prospectus supplement for primary offering
4:30pm
8-K
rwebf0bq
19 Nov 20
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
4:53pm
NT 10-K
lde2631l lkl6
28 Sep 20
Notice of late annual filing
4:30pm
8-K
s0kxuzgq2v 082k
4 Sep 20
NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference
4:05pm
8-K
uav9mqyrt4nmvj9jjvni
3 Aug 20
Entry into a Material Definitive Agreement
5:19pm
424B5
nq3cf2efgv5nreerl
31 Jul 20
Prospectus supplement for primary offering
5:29pm
8-K
pragqalmne26bxcyo
13 Jul 20
Nanoviricides Closes on $11.5 Million Underwritten Public Offering of Common Stock
4:52pm
424B5
qll fs1934inp1gq
9 Jul 20
Prospectus supplement for primary offering
5:13pm
424B5
zg4u12j
8 Jul 20
Prospectus supplement for primary offering
9:57pm
8-K
3j5hqw1eov aabdy
4 Jun 20
Departure of Directors or Certain Officers
4:49pm
8-K
vafvg9mqzpj6o
22 May 20
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering
4:10pm
424B5
d62mmqes
21 May 20
Prospectus supplement for primary offering
9:21pm
8-K
bt6 mm29d6gv7z
19 May 20
Departure of Directors or Certain Officers
5:15pm